awmsg logo



argatroban (Exembol®)


Reference No. 1405

Publication date:
23/01/2013


Last review date:
30/08/2016

Appraisal information

argatroban (Exembol®) 100 mg/ml concentrate for solution for infusion


Company: Mitsubishi Tanabe Pharma Europe Ltd
BNF category: Cardiovascular system
NMG meeting date: 07/11/2012
AWMSG meeting date: 12/12/2012
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 4312
Ministerial ratification: 16/01/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Argatroban (Exembol®) is recommended as an option for use within NHS Wales for anticoagulation in adult patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic therapy. The diagnosis should be confirmed by the HIPAA (heparin induced platelet activation assay) or an equivalent test. However, such confirmation must not delay the start of treatment.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download